BLAC vs. NVRO, INFU, TLSI, PDEX, SGHT, ZJYL, SRTS, TELA, ECOR, and LNSR
Should you be buying Bellevue Life Sciences Acquisition stock or one of its competitors? The main competitors of Bellevue Life Sciences Acquisition include Nevro (NVRO), InfuSystem (INFU), TriSalus Life Sciences (TLSI), Pro-Dex (PDEX), Sight Sciences (SGHT), Jin Medical International (ZJYL), Sensus Healthcare (SRTS), TELA Bio (TELA), electroCore (ECOR), and LENSAR (LNSR). These companies are all part of the "medical equipment" industry.
Bellevue Life Sciences Acquisition vs.
Nevro (NYSE:NVRO) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.
Bellevue Life Sciences Acquisition has lower revenue, but higher earnings than Nevro.
Nevro received 503 more outperform votes than Bellevue Life Sciences Acquisition when rated by MarketBeat users.
95.5% of Nevro shares are held by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. 3.2% of Nevro shares are held by company insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Nevro's net margin of -16.54%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Nevro's return on equity.
In the previous week, Bellevue Life Sciences Acquisition had 2 more articles in the media than Nevro. MarketBeat recorded 2 mentions for Bellevue Life Sciences Acquisition and 0 mentions for Nevro. Bellevue Life Sciences Acquisition's average media sentiment score of 0.85 beat Nevro's score of 0.00 indicating that Bellevue Life Sciences Acquisition is being referred to more favorably in the news media.
Nevro presently has a consensus target price of $6.30, suggesting a potential upside of 24.02%. Given Nevro's stronger consensus rating and higher possible upside, research analysts clearly believe Nevro is more favorable than Bellevue Life Sciences Acquisition.
Nevro has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500.
Summary
Nevro and Bellevue Life Sciences Acquisition tied by winning 6 of the 12 factors compared between the two stocks.
Get Bellevue Life Sciences Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bellevue Life Sciences Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:BLAC) was last updated on 2/1/2025 by MarketBeat.com Staff
